Scinovex
article Open AccessTop 1% cited

Seven-Year Efficacy and Safety of Treatment with Tenofovir Disoproxil Fumarate for Chronic Hepatitis B Virus Infection

Digestive Diseases and Sciences · 2014 · Vol. 60(5) · pp. 1457–1464
Marı́a ButiNaoky TsaiJoerg PetersenRobert FlisiakSelım GürelZahary KrastevRaul Aguilar SchallJohn F. FlahertyEduardo B. MartinsPrista CharuwornKathryn M. KitrinosG. Mani SubramanianEdward GanePatrick Marcellin

Abstract

Long-term TDF treatment was associated with sustained virologic, biochemical, and serologic responses, without resistance. TDF treatment was well tolerated, with a low incidence of renal and bone events. These data confirm the safety and efficacy of long-term TDF for CHB.

Hepatitis B Virus StudiesHepatitis C virus researchLiver Disease Diagnosis and TreatmentMedicineAdefovirInternal medicineGastroenterologyHBeAgHBsAgHepatologyCirrhosisAdverse effectHepatitis B virus

MeSH terms

AdenineAntiviral AgentsDNA, ViralDrug Administration ScheduleHepatitis B e AntigensHepatitis B virusHumansPhosphorous AcidsTime FactorsBiomarkersTreatment OutcomeViral LoadHepatitis B, ChronicDrug Resistance, Viral

Funding

  • Gilead Sciences
Citations
297
FWCI
19.52
field-weighted impact
References
23
Percentile
100%
vs. same field & year
Citations per year
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.